Back to top

Modified nucleotide triphosphates

A proven solution for mRNA therapeutic development

The use of modified nucleoside triphosphates (NTPs) has been instrumental in advancing mRNA therapeutic innovation, and TriLink® has been partnering with mRNA pioneers- since day one. Our modified NTPs are used in vaccine and therapeutic programs worldwide and continue to fuel the development of novel therapeutics. From research use to the first-ever GMP-grade offering, TriLink® provides a comprehensive portfolio of off-the-shelf, scalable, chemically synthesized NTP to help accelerate your mRNA therapeutic or vaccine development.


Promote robust expression and minimize immunogenicity

Incorporating modified uridines into mRNA products reduces immunogenicity, enhances mRNA stability, and increases translational capacity for more successful therapeutic action. TriLink’s broad catalog of 150+ modified NTPs, including N1-Methylpseudouridine-5’-Triphosphate,

5-Methoxyuridine-5’-Triphosphate, and Pseudouridine-5’-Triphosphate, are proven to optimize mRNA performance.

Highest-quality modified uridines for every stage and application

TriLink’s offerings of off-the-shelf, catalog, and customizable NTPs are available from RUO to GMP-grade to support diverse applications.

Related products and services

Unmodified NTPs

Our high-quality NTPs and dNTPs ensure robust results from PCR, RT-PCR, cDNA synthesis, sequencing, and in vitro mRNA transcription.


CleanCap® technology portfolio

CleanCap® analogs provide optimized co-transcriptional mRNA capping for vaccine and therapeutic applications.

mRNA CDMO services

TriLink’s discovery, preclinical, and clinical mRNA synthesis services help bring promising therapeutic candidates from the bench to the bedside.


NTP Brochure Download

TriLink BioTechnologies does not sell or distribute your information to 3rd parties. For more information, please refer to our Privacy Policy.